K. Löffler

A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium

A. Klippel, K. Giese, W. Arnold, 2006, Gene Therapy.

SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1

M. Muckenthaler, S. Dames, K. Löffler, 2019, HemaSphere.

Depletion of protein kinase N3 (PKN3) impairs actin and adherens junctions dynamics and attenuates endothelial cell activation.

A. Santel, K. Löffler, J. Kaufmann, 2012, European journal of cell biology.

Clinical Cancer esearch cer Therapy : Preclinical 027 Prevents Pulmonary Metastasis in Experimental and R ntaneous Mouse Metastasis Models

K. Giese, M. Aleku, O. Keil, 2010 .

Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models

K. Giese, A. Santel, M. Aleku, 2010, Clinical Cancer Research.

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.

M. Aleku, S. Dames, K. Löffler, 2022, Atherosclerosis.

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease

K. Löffler, Judith Hauptmann, E. Morrison, 2022, Toxicological sciences : an official journal of the Society of Toxicology.

Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.

B. Wiedenmann, K. Giese, W. Arnold, 2008, Cancer research.

RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy

A. Klippel, K. Giese, W. Arnold, 2006, Gene Therapy.

Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.

B. Wiedenmann, K. Giese, W. Arnold, 2008, Cancer research.